2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
14
Recurrence
3
Lymphoma, Non-Hodgkin
1
Leukemia, Plasma Cell
1
Leukemia, B-Cell
1
Infections
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Diseases
1
Interventions
Dexamethasone
10
fludarabine phosphate
9
Melphalan
9
fludarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
7
Cyclophosphamide
7
Mycophenolic Acid
6
Bortezomib
6
Tacrolimus
5
Calcium Dobesilate
4
filanesib
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
daratumumab
3
carfilzomib
3
auricularum
3
Stem Cell Transplantation
3
Sirolimus
3
Filgrastim
3
liposomal doxorubicin
2
ixazomib
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Cytarabine
2
Cyclosporine
2
Carmustine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Plasma Cell
×
idecabtagene vicleucel
×
Clear all
NCT06855121
2025-03-03
NIMMS
St. Olavs Hospital
Recruiting
400 enrolled